Company Overview and News
• Extension of BP option to acquire 42.5% equity in WA-359-P extended by 6 months until 25 October 2018
Cue Energy Resources Ltd (ASX:CUE ) today announced its FY18 First Half financial report which displays the ongoing out comes of the implementation of the Company strategy of maintaining a sustainable business that is focused on delivering disciplined growth and providing step change opportunities to maximise shareholder value. SUMMARY – 2018 First Half Financial Results
Melbourne, Australia; Cue Energy Resources L imited (ASX:CUE) is pleased to announce that the Sampang PSC Joint Venture has approved the drilling of the Paus Biru - 1 exploration well.
• Extension of BP option to acquire 42.5% equity in WA - 359 - P until 25 April 2018
Melbourne, Australia 29th Nov 2017; Cue Energy Resources Ltd (ASX:CUE) is pleased to advise that through its 100% owned subsidiary, Cue Exploration Pty Ltd, it has executed agreements with Beach Energy Limited (Beach) for Beach, subject to conditions and approvals, to acquire equity in North West Shelf exploration permits WA-359-P and WA-409-P in the Carnarvon Basin, offshore Western Australia, which contain the giant Ironbark gas prospect.
Cue Energy Resources Ltd (ASX:CUE) is pleased to advise that it has been notified by the National Offshore Petroleum Titles Administrator (NOPTA) of the approval of its application for a suspension of the Year 4 work program commitment for WA-389-P and extension of the permit term.
Singapore-based Zeta Energy Pte. Ltd., a wholly owned subsidiary of investment group Zeta Resources Ltd., has launched a partial offer for Wellington-based New Zealand Oil & Gas Ltd. (NZOG). If successful, Zeta would gain a 50.1% controlling interest in NZOG.
BP PLC reported that it has discovered 2 tcf of natural gas with two exploration wells drilled in the Columbus basin offshore the east coast of Trinidad and Tobago.
Oil prices rose slightly on May 29 in thin trading volumes because of the Memorial Day holiday in the US as well as UK and China holidays. Both benchmark crude oil prices in New York and London dropped on May 30 as typical trading resumed. Oil continued falling in early May 31 trading.
Husky Energy Inc. expects to start oil production from its West White Rose project offshore Newfoundland and Labrador in 2022 with a gross peak production rate of 75,000 b/d in 2025 (OGJ Online, July 28, 2015). The company and its partners will use a fixed wellhead platform tied back to the SeaRose floating production, storage, and offloading vessel, which began operations in 2005.
The US Atlantic region is likely to experience another above-normal hurricane season this year, National Oceanic & Atmospheric Administration forecasters said. For the upcoming Atlantic hurricane season from June 1 through Nov. 30, they forecast a 45% chance of an above-normal season, a 35% chance of a near-normal period, and only a 20% chance of a below-normal season.
Michigan’s two US senators, Democrats Gary C. Peters and Debbie Stabanow, introduced legislation aimed at increasing crude oil and products pipeline safety in and around the Great Lakes. One provision of S. 1226 would change the classification of such lines from onshore to a special category that would hold pipeline operators to liability standards like those for US offshore systems, they said.
Royal Dutch Shell PLC said it has signed an agreement to acquire the interests of Chevron Corp.’s subsidiary in Trinidad and Tobago. The deal, worth $250 million, includes Chevron’s holdings in East Coast Marine Area Blocks 6, 5a, and E.
Oil Search Ltd., Sydney and Port Moresby, has bought 30% interest in each of five permits in the Papua New Guinea eastern Foldbelt from ExxonMobil Corp.
Oil production will help Alberta and Saskatchewan recover from recession and lead Canadian provinces in economic growth this year, predicts the Conference Board of Canada (CBC).
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...